Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21552898 | 0.87 | KDM1A (0.34) | NOTUMSYKKDM1AKCNJ1GRIA1 | |
| SCHEMBL21564501 | 0.86 | MAPK8 (0.37) | NOTUM | |
| SCHEMBL21553063 | 0.84 | GRIA1 (0.38) | SYKGRIA1 | |
| SCHEMBL21552839 | 0.84 | NOTUM (0.35) | NOTUM | |
| SCHEMBL21552844 | 0.82 | SYK (0.37) | SYKGRIA1 | |
| SCHEMBL21553092 | 0.82 | NOTUM (0.34) | NOTUMSYKKDM1A | |
| SCHEMBL21553102 | 0.82 | EGLN2 (0.37) | NOTUMSYK | |
| SCHEMBL21553078 | 0.81 | DUT (0.36) | SYKKDM1AKCNJ1 | |
| SCHEMBL21552951 | 0.81 | PTGS2 (0.37) | SYK | |
| SCHEMBL26031857 | 0.81 | DYRK1A (0.33) | SYKGRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932629-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230250090-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230250090-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11578059-B2 | KDM1A inhibitors for the treatment of disease | Imago Biosciences. Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210115023-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2021-04-22 | — | — | US | disclosed |
| EP-3790867-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019217972-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932629-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | NOTUM 4680/4885SYK 2651/4885KDM1A 2/4885 |
| US-20230250090-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | NOTUM 4680/4885SYK 2651/4885KDM1A 2/4885 |
| US-20210115023-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1A, KDM1B, KDM2A | NOTUM 4635/4885SYK 2621/4885KDM1A 1/4885 |
| US-11578059-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | NOTUM 4680/4885SYK 2651/4885KDM1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.